$599

Lilly Sues More Compounders; Inventiva Completes Lanifibranor Ph3 Enrollment 

Two cardiometabolic news items have been observed: Lilly has sued Strive and Empower over compounded tirzepatide (view article); and Inventiva completed patient enrollment in its Ph3 NATiV3 study in MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here